Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death

Dong-Hee Choi1, Youn-Jung Kim, Young-Gun Kim

  • 1Neurology/Neuroscience Department, Weill Medical College of Cornell University, New York, New York 10065, USA.

Insights

Matrix metalloproteinase-3 (MMP3) cleaves alpha-synuclein in Parkinson disease (PD) brains. This MMP3 digestion generates toxic fragments, contributing to neurodegeneration and Lewy body formation in PD.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Alpha-synuclein aggregation and C-terminal truncation are implicated in Parkinson disease (PD).
  • Matrix metalloproteinase-3 (MMP3) is activated in dopaminergic (DA) cells under stress.

Purpose of the Study:

  • To investigate the role of MMP3 in cleaving alpha-synuclein in PD.
  • To determine the impact of MMP3-mediated alpha-synuclein cleavage on aggregation, Lewy body formation, and neurotoxicity.

Main Methods:

  • In vitro cleavage assays using purified alpha-synuclein and MMP3 catalytic domain (cMMP3).
  • Mass spectrometry and N-terminal determination to identify cleavage products.
  • Analysis of peptides in N27 DA cells under oxidative stress and MMP3 knockdown.
  • In vivo studies involving co-overexpression of cMMP3 and alpha-synuclein variants, and peptide overexpression in the substantia nigra.

Main Results:

  • MMP3 cleaves alpha-synuclein in vitro and in vivo, generating C-terminally truncated peptides (1-78, 1-91, 1-93).
  • A53T mutant alpha-synuclein produced higher quantities of these truncated peptides.
  • MMP3 knockdown attenuated peptide generation in stressed DA cells.
  • Co-overexpression of cMMP3 reduced insoluble aggregates but increased small aggregates.
  • Overexpression of the 1-93 peptide caused DA neuronal loss without Lewy body formation.

Conclusions:

  • MMP3-mediated cleavage of alpha-synuclein is a key event in PD pathogenesis.
  • This process influences alpha-synuclein aggregation, Lewy body formation, and DA neurotoxicity.
  • Targeting MMP3 activity may offer a therapeutic strategy for Parkinson disease.